CDH2 and central nervous system cancer: In the present study, miR-211 and pM treatments decreased the expression of mesenchymal markers (e.g., N-cadherin, vimentin and β-catenin) and enhanced the expression of the epithelial marker E-cadherin, thus inducing a MET-like phenotype in glioma cells.